Waldeck; Harald

Patent Applications and Registrations

Patent applications and USPTO patent grants for Waldeck; Harald.The latest application filed is for "sulfamate compounds and uses thereof".

Company Profile

0.10.13

Waldeck; Harald - Isernhagen DE
Waldeck; Harald - Isernhagen HB DE
Waldeck; Harald - Hannover DE
Waldeck; Harald - Hanover DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions Grant 8,058,264 - Firnges , et al. November 15, 2	2011-11-15
N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions Grant 7,772,225 - Antel , et al. August 10, 2	2010-08-10
N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof Grant 7,547,708 - Antel , et al. June 16, 2	2009-06-16
Sulfamate Compounds and Uses Thereof App 20090104126 - SCHOEN; Uwe ; et al.	2009-04-23
Method and pharmaceutical compositions for treating or inhibiting renal dysfunctions, diseases or disorders, particularly in diabetic patients Grant 7,273,860 - Thormaehlen , et al. September 25, 2	2007-09-25
N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions App 20070149512 - Antel; Jochen ; et al.	2007-06-28
N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof App 20070117823 - Antel; Jochen ; et al.	2007-05-24
Alkyl carbamate-substituted .beta.-lactones, process for their preparation, and pharmaceutical compositions containing them Grant 7,074,822 - Antel , et al. July 11, 2	2006-07-11
Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions App 20060128673 - Firnges; Michael ; et al.	2006-06-15
Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions App 20050261292 - Antel, Jochen ; et al.	2005-11-24
Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them App 20050197386 - Antel, Jochen ; et al.	2005-09-08
Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment Grant 6,930,207 - Antel , et al. August 16, 2	2005-08-16
Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity App 20050143441 - Antel, Jochen ; et al.	2005-06-30
Method and pharmaceutical compositions for treating or inhibiting renal dysfunctions, diseases or disorders, particularly in diabetic patients App 20050137183 - Thormaehlen, Dirk ; et al.	2005-06-23
Pharmaceutical composition with protective action against oxidative/toxic substances, especially cardiotoxic substances Grant 6,906,059 - Rozsa , et al. June 14, 2	2005-06-14
Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds App 20050124660 - Antel, Jochen ; et al.	2005-06-09
Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment App 20040214901 - Antel, Jochen ; et al.	2004-10-28
Compounds with NEP/MP-inhibitory activity and uses thereof App 20040162345 - Berger, Claudia ; et al.	2004-08-19
Pharmaceutical composition with protective action against oxidative/toxic substances, especially cardiotoxic substances App 20030040512 - Rozsa, Zsuzsanna ; et al.	2003-02-27
Pharmaceutical compositions and method for the treatment of hypertension App 20020052361 - Wilkins, Martin R. ; et al.	2002-05-02
Pharmaceuticals which promote gastrointestinal blood circulation Grant 5,783,573 - Rozsa , et al. July 21, 1	1998-07-21
Benzazepine-, benzoxazepine- and benzothiazepine-n-acetic acid derivatives, process for their preparation and pharmaceutical compositions containing them Grant 5,677,297 - Waldeck , et al. October 14, 1	1997-10-14
1,7-fused 1H-indole-2-carboxylic acid-N-(1,4-benzodiazepin-3-yl)amides Grant 5,010,076 - Waldeck , et al. April 23, 1	1991-04-23

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.